Cardiovascular
Olmesartan medoxomil
Brand: Olmetec®
PBAC's latest decision on Olmesartan medoxomil: Recommended (2005). Considered for treatment of hypertension.
PBAC outcome
Recommended
Unrestricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2005 → 2005
Eligible population
adults with hypertension
- Therapy area
- Cardiovascular
- Line of therapy
- Not applicable
- Evidence base
- RCT | Single-arm | Registry | Cost-minimisation
- Primary endpoint
- DBP, SBP
- Key trials
- 866-411, 866-204, 866-415, 866-318, 037, Kassler-Taub et al, Gradman et al, 038, 029, 030, 002, 025, 050
- Comparator
- irbesartan
- Economic model
- Cost-minimisation
- ICER note
- Cost-minimisation analysis conducted; no ICER calculated by design
Open on full dashboard →